Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by R013013Con May 20, 2020 1:31pm

475 Views

Post# 31052192

RE:What to choose?

iamronmexico wrote:
shrm pumped on nothing. Boss is run by the queen of pump and dumps f ing over shareholders MMED is in actual clinical trials (stage 2 now) and has Bruce Linton and Kevin O'Leary as shareholders. Take your pick.

I like Bruce Linton, but I don't like Kevin O'Leary. Regardless there is plenty of room for growth, but I expect it to take longer than most people are anticipating.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports